Replimune 股价在美国 FDA 接受皮肤癌药物潜在批准的重新提交后,涨幅超过一倍,最新上涨106.2%。
Replimune 股价在美国 FDA 接受皮肤癌药物潜在批准的重新提交后,涨幅超过一倍,最新上涨106.2%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.